Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines

Hanson, Charles; Köpf, I; Weijdegård, Birgitta; Weimarck, Anna; Stierner, Ulrika

doi:10.1097/00008390-199910000-00004

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings show that IFN‐α treatment induced a high degree of apoptosis (hypodiploid DNA peak, caspase‐3/7 activation and PARP cleavage) only in two (Me665/2/21 and HT‐144) of five melanoma cell lines tested. As also suggested by others, 9–11 the presence of IFN‐α receptors on target cells seemed to be a necessary but not a sufficient condition for cell sensitivity to IFN‐α. Our results, in fact, show that all cell lines expressed IFNA‐R mRNA, but its quantitative evaluation failed to correlate with the induction of apoptosis; in fact, the HT‐144 cell line, which showed the highest percentage of apoptosis, did not express the highest level of IFNA‐R mRNA; on the other hand, the highest expression of IFNA‐R mRNA was found in the SK‐Mel‐5 cell line, which proved to be poorly responsive to IFN‐α.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis

et al. 2003

View full text Add to dashboard Cite

Our results suggest that the effects of IFN-alpha on hTERT and TA can result from the induction of apoptosis, but they can also occur through a direct modulation of hTERT. We hypothesize that, depending on the cellular context rather than the IFNA-R status of the targeted cells, IFN-alpha can elicit an apoptotic cell death; furthermore, different pathways of apoptosis, not necessarily involving telomerase, can be put into motion.

show abstract

Section: Discussionmentioning

confidence: 55%

“…Furthermore, it has been demonstrated that high concentrations of IFN‐α induce apoptosis 3,5 . The effects of IFN‐α seem to be transient and to depend both on its concentration in the microenvironment and on cell sensitivity, the latter being related to the expression of IFN‐α receptor (IFNA‐R) and IFN genes 9–11 …”

mentioning

confidence: 99%

Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…In addition, the sensitivity to the extrinsically supplied IFN correlates with expression of endogenous IFN genes, and the melanoma cells with enhanced endogenous IFN production may respond more positively to IFN treatment 14 . Therefore, there may have recently been few in‐transit metastases in the current case because the melanoma cells might have expressed endogenous IFN genes and thus responded positively to the IFN treatment.…”

Section: Discussionmentioning

confidence: 93%

Case of cutaneous malignant melanoma surviving 16 years with late recurrence

Otsu

Fukui

Iki

et al. 2009

The Journal of Dermatology

View full text Add to dashboard Cite

Late recurrence, defined as that occurring 10 or more years after diagnosis, is an unusual event in cutaneous malignant melanoma (MM). A 59-year-old woman presented with a black nodule measuring 10 mm x 9 mm on the sole of her right foot. She was diagnosed with MM and the tumor was totally excised with 5 cm of the normal surrounding skin. Eleven years after the operation, five in-transit metastases were found in her right limb. They were all excised and beta-interferon (IFN-beta) was injected into the skin around the postoperative scars. However, numerous new in-transit skin metastases have been emerging every year in her right limb. Fifty-four in-transit skin metastases have so far been found. Recently, there have been few in-transit metastases. All in-transit metastatic lesions were excised and local IFN-beta injections were conducted continuously. There is no evidence of metastases to the internal organs or lymph nodes. This report describes this case with a brief review of the published work concerning the rare late recurrences of MM.

show abstract

“…Susceptibility to extrinsically supplied IFN-β protein correlated closely with the amount of intracellular IFN-β mRNA in cultured human glioma cells, in agreement with the findings of Hanson et al in melanoma cell lines. 19) It was also confirmed that there is a significant prolongation of phosphorylation time of several proteins involved in the intracellular signal transduction pathway of IFN-β, such as JAK1, Tyk2, and STAT-1. This apoptotic process did not involve caspase-3 or 8 activation and cleavage of DFF45/ICAD, but activation of caspase-7 and DNase γ was detected.…”

Section: -3 Antitumor Mechanisms Of Ifn-β β β β Gene Transfermentioning

confidence: 83%

lnterferon‐β gene therapy for cancer: Basic research to clinical application

2004

View full text Add to dashboard Cite

Interferon‐β gene therapy for cancer is the first such protocol developed in Japan. Here we describe the development process of our interferon‐β gene therapy from basic research to clinical application. Interestingly, the biological and biochemical characteristics of interferon‐β gene therapy through transfer of the interferon‐(gene into tumor cells by means of cationic liposomes differed from those of conventional interferon‐β protein therapy. Interferon‐β gene transfer could induce apoptosis in interferon‐β protein‐resistant tumor cells, such as glioma, melanoma, and renal cell carcinoma. Induction of apoptosis was related to the level of intracellular mRNA of interferon‐β, prolongation of the phos‐phorylation time of molecules in the interferon‐p signal transduc‐tion pathway, such as JAK1, Trk2, and STAT1, and activation of DNase γ. In our preclinical study we developed lyophilized cat‐ionic liposomes containing interferon‐β gene (gene drug) for clinical use and confirmed their safety. Thereafter, we performed a pilot clinical trial in patients with malignant glioma and confirmed the safety and effectiveness of this interferon‐β gene therapy. In this review we also comment on the status of gene therapy regulation in Japan. Interferon‐β gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

show abstract

Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines

Cited by 10 publications

References 0 publications

Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis

Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis

Case of cutaneous malignant melanoma surviving 16 years with late recurrence

lnterferon‐β gene therapy for cancer: Basic research to clinical application

Contact Info

Product

Resources

About